My point is simple: Corx is trying to partner a drug for RD, which is not a CNS area that would be impacted by a reduction in CNS research of a larger pharma.
Traditionally, Corx was strictly a CNS R&D company. If they are desperately trying to focus on an ADHD deal--which I have suggested is a futile effort since the FDA shoot-down anyway, mostly because it is a 'soft' indication--then what you say makes much more sense. However, I still think tremendous resources will be plowed into Alzheimer's R&D, so the cutbacks in CNS drug development should be categorized by the type of indication.
Neuro-there are always going to be obstacles, no matter what you are dealing with, but turning them into excuses (i.e. 'insurmountable') is self-defeating and facilitates failure.
Market Data 
Markets 
AI
